Transdermal Patch for Acidic Cannabinoid Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current transdermal delivery methods for cannabinoids do not effectively deliver the acidic forms of cannabinoids, such as THCA, CBDA, and CBCA, which have distinct medicinal properties different from their decarboxylated counterparts, limiting their therapeutic potential.
Innovation Solution
A raw cannabis composition comprising cannabis biomass dispersed in a transdermal carrier, specifically designed to include an anesthetically effective amount of tetrahydrocannabinolic acid (THCA) and minor cannabinoid acid compounds, substantially free from their decarboxylated forms, combined with terpenes and flavonoids, and formulated into a skin patch for transdermal administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If transdermal delivery methods are used for cannabinoids, then delivery of decarboxylated forms (THC, CBD, CBC) is achieved, but delivery of acidic forms (THCA, CBDA, CBCA) with distinct medicinal properties is not effectively achieved
Solution Approach 1:
The patent changes the chemical parameter of the cannabinoid from decarboxylated forms to acidic forms by controlling the processing conditions. Specifically, the biomass is processed at temperatures below the decarboxylation threshold (maintained under 104°C or 400°F) to preserve the carboxylic acid groups, thereby delivering THCA, CBDA, and CBCA instead of their decarboxylated counterparts through the transdermal carrier.
2Object-generated harmful factors
If decarboxylated cannabinoid forms are delivered transdermally, then psychoactive effects are produced, but analgesic benefits without psychoactivity are limited
Solution Approach 1:
The patent extracts and isolates the acidic cannabinoid compounds (THCA, CBDA, CBCA) from the cannabis biomass through controlled processing that prevents decarboxylation. This extraction of the acidic forms specifically, without converting them to their psychoactive decarboxylated counterparts, enables delivery of analgesic benefits without the harmful psychoactive effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the targeted delivery of acidic cannabinoids, providing analgesic and therapeutic benefits without the psychoactive effects associated with decarboxylated forms, offering a unique and effective treatment for pain and other medical conditions through transdermal absorption.
Implementation Method 1
transdermal delivery of a formulation of raw cannabinoids
Data Source
AI summary
The present disclosure provides a raw cannabis composition, the raw cannabis composition comprises a cannabis biomass dispersed in a transdermal carrier, and the cannabis biomass composition comprises an anesthetically effective amount of a cannabinoid acid compound and is substantially free from the cannabinoid acid compound in its decarboxylated form. The cannabinoid acid compound comprises a major cannabinoid acid compound that is tetrahydrocannabinolic acid (“THCA”) and a minor cannabinoid acid compound other than THCA. Methods of making and using the raw cannabis composition are also disclosed.